Neuromuscular blockade is an anesthetic technique that allows clinicians to immobilize patients in a controlled way and safely perform precise, complex surgery. Nondepolarizing neuromuscular blocking agents (NMBAs) such as rocuronium and vecuronium produce paralysis by competitively inhibiting nicotinic acetylcholine receptors (nAChRs) at the motor endplate, preventing acetylcholine (ACh) from activating the receptor to generate muscle contraction. Agents used for the reversal of neuromuscular blockade operate through two fundamentally different molecular strategies: boosting synaptic ACh by inhibiting acetylcholinesterase (AChE) or directly removing aminosteroid NMBAs from circulation through host-guest encapsulation. Each method has distinct molecular targets, kinetics, and side-effect profiles that shape clinical use and guide ongoing drug development.1
AChE contains two key functional regions: an anionic site that attracts the positively charged ammonium of ACh and an esteratic site that catalyzes hydrolysis. Neostigmine is a neuromuscular blockade reversal agent that works on a molecular level by inhibiting AChE, allowing ACh to build up and disrupt the competitive inhibition of the blocking agent. It is a quaternary ammonium carbamate that binds deep within the enzyme’s gorge, occupying both the anionic and esteratic domains. This interaction forms a carbamylated enzyme intermediate that is hydrolyzed far more slowly than the natural substrate.1 As long as the esteratic site remains carbamylated, ACh cannot access the catalytic machinery, effectively inhibiting AChE until spontaneous decarbamylation restores activity.1
By inhibiting AChE, neostigmine prolongs the synaptic lifetime of ACh and raises its steady-state concentration at the neuromuscular junction. Elevated ACh then competes more effectively with nondepolarizing NMBAs for nAChR binding. As circulating NMBA levels fall through redistribution and elimination, ACh occupancy of the receptor increases, allowing endplate potentials to return above the threshold needed for muscle contraction.1 However, this approach is limited by a ceiling effect: once AChE is maximally inhibited, additional drug provides no further benefit, especially in deep blockade. Muscarinic side effects—bradycardia, secretions, bronchospasm—require co-administration of anticholinergics.
Host-guest encapsulation offers a fundamentally different molecular mechanism for neuromuscular blockade reversal. Sugammadex, a modified γ-cyclodextrin, features a hydrophobic central cavity and negatively charged exterior groups. The cavity fits the hydrophobic steroid backbone of rocuronium and vecuronium, while the outer charges attract their cationic regions, enabling tight but reversible 1:1 binding.2, 3 Molecular simulations show that rocuronium first docks near the rim of sugammadex, then rotates and slides into the cavity to reach a low-energy, stable configuration.3
Clinically, sugammadex rapidly decreases the free plasma concentration of rocuronium or vecuronium by encapsulating them. This creates a concentration gradient that draws more NMBA molecules away from the neuromuscular junction and into the bloodstream. Once removed from the receptor environment, paralysis resolves without needing to increase ACh levels or inhibit AChE.3
Calabadions represent the next generation of encapsulating agents. These pumpkin-shaped molecular “containers,” derived from the cucurbituril family, bind multiple classes of cationic NMBAs, including steroidal and benzylisoquinolinium drugs.2 Calabadion 1 has affinity comparable to the sugammadex–rocuronium complex, while calabadion 2 exhibits dramatically higher binding strength—approximately two orders of magnitude greater than sugammadex in
experimental systems. In vitro and ex vivo studies show calabadion 2 binds rocuronium with roughly 89-fold higher affinity than sugammadex.2,4 Its adjustable cavity size allows encapsulation of benzylisoquinoliniums like cisatracurium, expanding its therapeutic reach beyond what sugammadex can achieve.2,4
These complexes are cleared renally, and animal studies demonstrate that calabadion 2 reverses neuromuscular block more rapidly and at lower doses than sugammadex, without major cardiovascular effects.2,4 Because calabadions do not rely on increasing ACh, they avoid muscarinic adverse effects and the ceiling limitation of AChE inhibitors, and they may work even in profound blockade. Their main barriers to clinical adoption include defining dosing in relation to NMBA burden, assessing off-target binding to other cationic drugs, and establishing human safety. Current evidence remains preclinical, but if validated, calabadions could function as broad—potentially universal—NMBA reversal agents.
The molecular mechanisms behind neuromuscular blockade reversal define both the strengths and limits of current therapy. Traditional AChE inhibitors like neostigmine boost synaptic acetylcholine. However, they only work when NMBA levels are low, and they bring muscarinic side effects and a ceiling on efficacy. Encapsulation agents such as sugammadex mark a real shift: by directly sequestering NMBAs, they allow rapid, reliable reversal even from deep block with fewer autonomic complications. Emerging calabadions may extend this model further, potentially offering universal reversal across NMBA classes.
References
1. Ji W, Zhang X, Liu J, et al. Efficacy and safety of neostigmine for neuromuscular blockade reversal in patients under general anesthesia: a systematic review and meta-analysis. Ann Transl Med. 2021;9(22):1691. doi:10.21037/atm-21-5667
2. Haerter F, Simons JCP, Foerster U, et al. Comparative effectiveness of calabadion and sugammadex to reverse non-depolarizing neuromuscular blocking agents. Anesthesiology. 2015;123(6):1337-1349. doi:10.1097/ALN.0000000000000868
3. Irani AH, Voss L, Whittle N, Sleigh JW. Encapsulation Dynamics of Neuromuscular Blocking Drugs by Sugammadex. Anesthesiology. 2023;138(2):152-163. doi:10.1097/ALN.0000000000004442
4. de Boer HD, Carlos RV. New drug developments for neuromuscular blockade and reversal: Gantacurium, CW002, CW011, and calabadion. Curr Anesthesiol Rep. 2018;8(1):119-124. doi:10.1007/s40140-018-0262-9